ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection
Skip to content
The CRC Digest
◇ RESEARCH
ctDNA Shows Promise for Risk Stratification but Mixed Results for Treatment Selection
A review of circulating tumor DNA in GI cancers found that while postoperative ctDNA positivity identifies high-risk patients, recent trials show mixed results: DYNAMIC-III showed escalation in ctDNA-positive stage III disease